Drug Trial Radar · NCT03444714
Phase I Study of RiMO-301 With Radiation in Advanced Tumors
Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Apr 10, 2018
Primary completion
Jun 16, 2025
Study completion Jun 16, 2025
Sponsor
- Lead sponsor
- Coordination Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Chicago
- First posted
- Feb 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes. Condition or Disease: Patient with advanced tumor which is clinically accessible for intratumoral injection Intervention/Treatment: Drug - RiMO-301 Radiation - Radiotherapy Phase: Phase 1
Conditions
- Advanced Tumors
Interventions
RiMO-301Drug
Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: 45 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Illinois at Chicago
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.